NeuRank: learning to rank with neural networks for drug-target interaction prediction.
BMC Bioinformatics
; 22(1): 567, 2021 Nov 26.
Article
en En
| MEDLINE
| ID: mdl-34836495
BACKGROUND: Experimental verification of a drug discovery process is expensive and time-consuming. Therefore, recently, the demand to more efficiently and effectively identify drug-target interactions (DTIs) has intensified. RESULTS: We treat the prediction of DTIs as a ranking problem and propose a neural network architecture, NeuRank, to address it. Also, we assume that similar drug compounds are likely to interact with similar target proteins. Thus, in our model, we add drug and target similarities, which are very effective at improving the prediction of DTIs. Then, we develop NeuRank from a point-wise to a pair-wise, and further to list-wise model. CONCLUSION: Finally, results from extensive experiments on five public data sets (DrugBank, Enzymes, Ion Channels, G-Protein-Coupled Receptors, and Nuclear Receptors) show that, in identifying DTIs, our models achieve better performance than other state-of-the-art methods.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Preparaciones Farmacéuticas
/
Desarrollo de Medicamentos
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
BMC Bioinformatics
Asunto de la revista:
INFORMATICA MEDICA
Año:
2021
Tipo del documento:
Article
País de afiliación:
China